Iressa shows first-line benefit in NSCLC in selected Asian patients
This article was originally published in Scrip
Executive Summary
AstraZenecahas released preliminary results from a large-scale Asian study with its anticancer Iressa (gefitinib), which showed a benefit in progression-free survival (PFS) over carboplatin plus paclitaxel in the first-line treatment of selected non-small cell lung cancer (NSCLC) patients.